Angiotensin-converting enzyme inhibitors (ACEis) have been used to treat anthracycline (ANT)-induced cardiac dysfunction, and they appear beneficial for secondary prevention in high-risk patients. However, it remains unclear whether they truly prevent ANT-induced cardiac damage and provide long-lasting cardioprotection. The present study aimed to examine the cardioprotective effects of perindopril on chronic ANT cardiotoxicity in a rabbit model previously validated with the cardioprotective agent dexrazoxane (DEX) with focus on post-treatment follow-up (FU). Chronic cardiotoxicity was induced by daunorubicin (DAU; 3 mg/kg/week for 10 weeks). Perindopril (0.05 mg/kg/day) was administered before and throughout chronic DAU treatment. After the completion of treatment, significant benefits were observed in perindopril co-treated animals, particularly full prevention of DAU-induced mortality and prevention or significant reductions in cardiac dysfunction, plasma cardiac troponin T (cTnT) levels, morphological damage, and most of the myocardial molecular alterations. However, these benefits significantly waned during 3 weeks of drug-free FU, which was not salvageable by administering a higher perindopril dose. In the longer (10-week) FU period, further worsening of left ventricular function and morphological damage occurred together with heart failure (HF)-related mortality. Continued perindopril treatment in the FU period did not reverse this trend but prevented HF-related mortality and reduced the severity of the progression of cardiac damage. These findings contrasted with the robust long-lasting protection observed previously for DEX in the same model. Hence, in the present study, perindopril provided only temporary control of ANT cardiotoxicity development, which may be associated with the lack of effects on ANT-induced and topoisomerase II β (TOP2B)-dependent DNA damage responses in the heart.

Department of Biochemical Sciences Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Clinical Biochemistry and Diagnostics Faculty of Medicine in Hradec Králové Charles University and University Hospital Hradec Králové Hradec Králové Czech Republic

Department of Histology and Embryology Faculty of Medicine in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Pharmacology Faculty of Medicine in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Physiology Faculty of Medicine in Hradec Králové Charles University Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22011323

003      

CZ-PrNML

005      

20220506130509.0

007      

ta

008      

220425s2022 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1042/CS20210836 $2 doi

035    __

$a (PubMed)34878093

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Pokorná, Zuzana $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic

245    10

$a Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up / $c Z. Pokorná, P. Kollárová-Brázdová, O. Lenčová-Popelová, E. Jirkovský, J. Kubeš, Y. Mazurová, M. Adamcová, M. Holečková, V. Palička, T. Šimůnek, M. Štěrba

520    9_

$a Angiotensin-converting enzyme inhibitors (ACEis) have been used to treat anthracycline (ANT)-induced cardiac dysfunction, and they appear beneficial for secondary prevention in high-risk patients. However, it remains unclear whether they truly prevent ANT-induced cardiac damage and provide long-lasting cardioprotection. The present study aimed to examine the cardioprotective effects of perindopril on chronic ANT cardiotoxicity in a rabbit model previously validated with the cardioprotective agent dexrazoxane (DEX) with focus on post-treatment follow-up (FU). Chronic cardiotoxicity was induced by daunorubicin (DAU; 3 mg/kg/week for 10 weeks). Perindopril (0.05 mg/kg/day) was administered before and throughout chronic DAU treatment. After the completion of treatment, significant benefits were observed in perindopril co-treated animals, particularly full prevention of DAU-induced mortality and prevention or significant reductions in cardiac dysfunction, plasma cardiac troponin T (cTnT) levels, morphological damage, and most of the myocardial molecular alterations. However, these benefits significantly waned during 3 weeks of drug-free FU, which was not salvageable by administering a higher perindopril dose. In the longer (10-week) FU period, further worsening of left ventricular function and morphological damage occurred together with heart failure (HF)-related mortality. Continued perindopril treatment in the FU period did not reverse this trend but prevented HF-related mortality and reduced the severity of the progression of cardiac damage. These findings contrasted with the robust long-lasting protection observed previously for DEX in the same model. Hence, in the present study, perindopril provided only temporary control of ANT cardiotoxicity development, which may be associated with the lack of effects on ANT-induced and topoisomerase II β (TOP2B)-dependent DNA damage responses in the heart.

650    _2

$a inhibitory ACE $x terapeutické užití $7 D000806

650    _2

$a zvířata $7 D000818

650    _2

$a antibiotika antitumorózní $7 D000903

650    _2

$a kardiotoxicita $x farmakoterapie $x prevence a kontrola $7 D066126

650    _2

$a daunomycin $x škodlivé účinky $7 D003630

650    _2

$a nemoci srdce $x chemicky indukované $x prevence a kontrola $7 D006331

650    _2

$a srdeční selhání $x farmakoterapie $x mortalita $7 D006333

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a perindopril $x terapeutické užití $7 D020913

650    _2

$a králíci $7 D011817

650    _2

$a troponin T $x krev $7 D020107

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Kollárová-Brázdová, Petra $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic

700    1_

$a Lenčová-Popelová, Olga $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic

700    1_

$a Jirkovský, Eduard $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic

700    1_

$a Kubeš, Jan $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic

700    1_

$a Mazurová, Yvona $u Department of Histology and Embryology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic

700    1_

$a Adamcová, Michaela $u Department of Physiology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic

700    1_

$a Holečková, Magdalena $u Department of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Králové, Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic

700    1_

$a Palička, Vladimír $u Department of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Králové, Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic

700    1_

$a Šimůnek, Tomáš $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic

700    1_

$a Štěrba, Martin $u Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic $1 https://orcid.org/0000000301457697 $7 xx0076492

773    0_

$w MED00009494 $t Clinical science (London, England : 1979) $x 1470-8736 $g Roč. 136, č. 1 (2022), s. 139-161

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34878093 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20220506130501 $b ABA008

999    __

$a ok $b bmc $g 1789086 $s 1162521

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 136 $c 1 $d 139-161 $e 20220114 $i 1470-8736 $m Clinical science (1979) $n Clin Sci (Lond) $x MED00009494

LZP    __

$a Pubmed-20220425